Literature DB >> 20074859

Glucose metabolism in burn patients: the role of insulin and other endocrine hormones.

Nikiforos Ballian1, Atoosa Rabiee, Dana K Andersen, Dariush Elahi, B Robert Gibson.   

Abstract

Severe burn causes a catabolic response with profound effects on glucose and muscle protein metabolism. This response is characterized by hyperglycemia and loss of muscle mass, both of which have been associated with significantly increased morbidity and mortality. In critically ill surgical patients, obtaining tight glycemic control with intensive insulin therapy was shown to reduce morbidity and mortality and has increasingly become the standard of care. In addition to its well-known anti-hyperglycemic action and reduction in infections, insulin promotes muscle anabolism and regulates the systemic inflammatory response. Despite a demonstrated benefit of insulin administration on the maintenance of skeletal muscle mass, it is unknown if this effect translates to improved clinical outcomes in the thermally injured. Further, insulin therapy has the potential to cause hypoglycemia and requires frequent monitoring of blood glucose levels. A better understanding of the clinical benefit associated with tight glycemic control in the burned patient, as well as newer strategies to achieve and maintain that control, may provide improved methods to reduce the clinical morbidity and mortality in the thermally injured patient.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20074859     DOI: 10.1016/j.burns.2009.11.008

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  9 in total

1.  Diabetes does not influence selected clinical outcomes in critically ill burn patients.

Authors:  Chaitanya K Dahagam; Alejandra Mora; Steven E Wolf; Charles E Wade
Journal:  J Burn Care Res       Date:  2011 Mar-Apr       Impact factor: 1.845

Review 2.  Diabetes mellitus and burns. Part I-basic science and implications for management.

Authors:  Ioannis Goutos; Rebecca Spenser Nicholas; Atisha A Pandya; Sudip J Ghosh
Journal:  Int J Burns Trauma       Date:  2015-03-20

Review 3.  Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned.

Authors:  Eduardo I Gus; Shahriar Shahrokhi; Marc G Jeschke
Journal:  Burns       Date:  2019-12-15       Impact factor: 2.744

4.  Clinical impact of sample interference on intensive insulin therapy in severely burned patients: a pilot study.

Authors:  Nam K Tran; Zachary R Godwin; Jennifer C Bockhold; Anthony G Passerini; Julian Cheng; Morgan Ingemason
Journal:  J Burn Care Res       Date:  2014 Jan-Feb       Impact factor: 1.845

Review 5.  Hindbrain astrocytes and glucose counter-regulation.

Authors:  Richard C Rogers; Gerlinda E Hermann
Journal:  Physiol Behav       Date:  2019-02-21

6.  Lytic cocktail: An effective method to alleviate severe burn induced hyper-metabolism through regulating white adipose tissue browning.

Authors:  Meng Zhang; Peilang Yang; Tianyi Yu; Martin C Harmsen; Min Gao; Dan Liu; Yan Shi; Yan Liu; Xiong Zhang
Journal:  Heliyon       Date:  2022-03-17

7.  Thrombin action on astrocytes in the hindbrain of the rat disrupts glycemic and respiratory control.

Authors:  Richard C Rogers; Eileen M Hasser; Gerlinda E Hermann
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-04-22       Impact factor: 3.619

8.  The reduced bactericidal activity of neutrophils as an incisive indicator of water-immersion restraint stress and impaired exercise performance in mice.

Authors:  Manabu Kinoshita; Hiroyuki Nakashima; Masahiro Nakashima; Minori Koga; Hiroyuki Toda; Kazuki Koiwai; Yuji Morimoto; Hiromi Miyazaki; Daizoh Saitoh; Hiroaki Suzuki; Shuhji Seki
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

9.  Identification of Novel Biomarkers With Diagnostic Value and Immune Infiltration in Burn Injury.

Authors:  Sitong Zhou; Kangchun Wang; Jingru Wang; Jia He; Wenlian Zheng; Chengmin Long; Xiaodong Chen; Ronghua Yang
Journal:  Front Genet       Date:  2022-03-22       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.